Antiphospholipid syndrome is accepted as one of the most important causes of hypercoagulable states. Thrombotic events in patients with antiphospholipid syndrome, predominantly women, occur at a younger age than in those suffering from atherosclerotic disease. The majority of the thrombotic events affect the deep venous system of the lower limbs and arterial thrombosis predominates in the cerebral territory. The use of anticoagulant therapy prevents recurrent thrombosis but the duration and intensity of treatment remain controversial. Aortic disease is an anecdotal fact in the literature. A case of infrarenal aortic occlusion involving both iliac arteries associated with primary antiphospholipid syndrome is presented.
Get full access to this article
View all access options for this article.
References
1.
1. Petri M: Pathogenesis and treatment of the antiphospholipid antibody syndrome. Med Clin North Am81:151-177, 1997.
2.
2. Lee RW, Lloyd MT Jr, Landry GJ, et al: Prospective comparison of infrainguinal bypass grafting in patients with and without antiphospholipid antibodies. J Vasc Surg24:524-533, 1996.
10. Ghirardello A, Doria A, Ruffatti A, et al: Antiphospholipid antibodies in systemic lupus erythematosus. Are they specific tools for the diagnosis of aPL syndrome? Ann Rheum Dis53:140-142, 1994.
11.
11. Khamashta MA, Cuadrado MA, Mujic F, et al: The management of thrombosis in the antiphospholipidantibody syndrome. N Engl J Med332:993-997, 1995.
12.
12. Forastiero RR, Martinuzzo ME, Cerrato GS, et al: Relationship of anti B2-glycoprotein I and anti prothrombin antibodies to thrombosis and pregnancy loss in patients with antiphospholipid antibodies. Thromb Haemost78:1008-1014, 1997.
13.
13. Rosove MH, Brewer PMC: Antiphospholipid thrombosis: Clinical course after the first thrombotic event in 70 patients. Ann Intern Med117:303-308, 1992.
14.
14. Krnic-Barrie S, Riester O'Connor C, Looney SW et al: A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis. Arch Intern Med157:2101-2108, 1997.
15.
15. McGee GS, Pearce WH, Sharma L, et al: Antiphospholipid antibodies and arterial thrombosis. Arch Surg127:342-346, 1992.
16.
16. Insko EK, Haskal ZJ: Antiphospholipid syndrome: Patterns of life-threatening and severe recurrent vascular complications. Radiology202:319-326, 1997.
17.
17. Atsumi T, Khamashta MA, Haworth RS, et al: Arterial disease and thrombosis in the antiphospholipid syndrome. A pathogenic role for endothelin I. Arthritis Rheum41:800-807, 1998.
18.
18. Atsumi T, Khamashta MA, Andujar C, et al: Elevated plasma lipoprotein(a) level and its association with impaired fibrinolysis in patients with antiphospholipid syndrome. J Rheumatol25:69-73, 1998.
19.
19. Martinez-Vaizquez C, Albo C, Rivera A, et al: Sindrome antifosfolipido primario. Aspectos clinicoevolutivos de 24 casos. Rev Clin Esp194:164-169, 1994.
20.
20. Whitemore AD, Pearce WH, Yao JST, et al: Detection and treatment of hypercoagulable states: Can they improve infrainguinal bypass results? Presented at the Symposium on Current Critical Problems and New Horizons in Vascular Surgery, New York, November 16-18, 1990.
21.
21. Galli M, Cortellazo S, Barbui T: In vivo efficacy of intravenous gammaglobulins in patients with lupus anticoagulant is not mediated by an anti-idiotypic mechanism. Am J Haematol38:184-188, 1991.
22.
22. Nojima E, Suehisa E, Akita N, et al: Risk of arterial thrombosis with anticardiolipin antibodies and lupus anticoagulant. Br J Haematol96:447-450, 1997.
23.
23. Branch DW: Thoughts on the mechanism of pregnancy loss associated with the antiphospholipid syndrome. Lupus3:275-280, 1994.
24.
24. Derksen RHWM, de Groot PG, Kater L, et al: Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann Rheum Dis52:689-692, 1993.
